Why the study?
Does experimental sIPV provide comparable immunogenicity and protection as cIPV in transgenic mice?
Does experimental sIPV provide comparable immunogenicity and protection as cIPV in transgenic mice?
Experimental serotype 1 sIPV demonstrates comparable immunogenicity and superior protection compared to conventional IPV in a transgenic mouse model.
Supports sIPV development in animal models; leaves open translation to human polio immunization.
Recently, we developed and optimized a new method for the evaluation of the protective properties of serotype 2 inactivated poliovirus vaccines (IPV). The method is based on the immunization and subsequent challenge of transgenic (Tg) mice susceptible to poliovirus. We describe a similar method for the assessment of the protectiveness of serotype 1 IPV and demonstrate that experimental IPV produced from attenuated Sabin strain (sIPV) of serotype 1 poliovirus induced serum neutralizing antibodies, immunoglobulin (Ig) G, IgM, and salivary IgA at titers comparable to those induced by conventional IPV (cIPV) produced from the wild-type Mahoney strain. In contrast to our previous results with serotype 2 sIPV, serotype 1 sIPV provided even better protection of Tg mice than cIPV against challenge with wild-type Mahoney strain.
No takes yet. Share an insight, caveat, or question.
Dragunsky et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from The Journal of Infectious Diseases